

The Impact of Drugs on Muscle Tone: A Comprehensive Analysis
Abstract
Muscle tone is responsible for maintaining picture, stability and movement. Muscle relaxants such as baclofen, diazepam and cyclobenzaprime are commonly used to alleviate muscle spasms and stiffness. These drugs work by targeting the central nervous system, especially the Spinal cord and brain, to decrease muscle activity and promote relaxation. Drugs like amphetamine, caffeine and cocaine exhibit their stimulant effects on the body. Stimulants can enhance muscle tone bt stimulating the release of neurotransmitters such as Dopamine and nor epinephrine, which activate the sympathetic system. Depressant drugs, including alcohol, opioid and benzodiapines have a relaxing effect especially on the central nervous system. A typical substance used by body builders and athletes to enhance muscle growth and performance is synthetic derivative of testosterone called anabolic androngenic steroids, or AAS. Extended usage of anabolic steroids may lead to muscular dystrophy, tendon damage, and cardiovascular issues. Certain medications prescribed for neurological conditions, such as Parkinsons disease and multiple sclerosis, can impact muscle tone. Generally, medications that block Dopamine receptors, such as anti psychotic, may induce muscle stiffness as well as rigidity as side effects. Finally it is concluded that the impact of drugs on muscle tone is complex and multifaceted, with various substances exerting different effects on the neuro muscular system.
References
Lance JW. What is spasticity? Lancet. 1990 Mar 10;335(8689):606. [PubMed]
Kheder A, Nair KP. Spasticity: pathophysiology, evaluation and management. Pract Neurol. 2012 Oct;12(5):289-98. [PubMed]
Escaldi SV, Cuccurullo SJ, Terzella M, Petagna AM, Strax TE. Assessing competency in spasticity management: a method of development and assessment. Am J Phys Med Rehabil. 2012 Mar;91(3):243-53. [PubMed]
Rekand T. Clinical assessment and management of spasticity: a review. Acta Neurol Scand Suppl. 2010;(190):62-6. [PubMed]
Emos MC, Agarwal S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 14, 2023. Neuroanatomy, Upper Motor Neuron Lesion. [PMC free article] [PubMed]
Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T. A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Crit Rev Phys Rehabil Med. 2013;25(1-2):11-22. [PMC free article] [PubMed]
Bochkezanian V, Newton RU, Trajano GS, Blazevich AJ. Effects of Neuromuscular Electrical Stimulation in People with Spinal Cord Injury. Med Sci Sports Exerc. 2018 Sep;50(9):1733-1739. [PubMed]
Chang EY, Ehsan A. Placement of Baclofen Pump Catheter Tip for Upper Extremity Spasticity Management. Neuromodulation. 2018 Oct;21(7):714-716. [PubMed]
Mehrholz J, Wagner K, Meissner D, Grundmann K, Zange C, Koch R, Pohl M. Reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in adult patients with severe brain injury: a comparison study. Clin Rehabil. 2005 Oct;19(7):751-9. [PubMed]
Gracies JM. Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Phys Med Rehabil Clin N Am. 2001 Nov;12(4):747-68, vi. [PubMed]
Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. [PubMed]
Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med. 2010 Sep;46(3):401-10. [PubMed]
Abbruzzese G. The medical management of spasticity. Eur J Neurol. 2002 May;9 Suppl 1:30-4; discussion 53-61. [PubMed]
Kim JH, Jung NY, Chang WS, Jung HH, Cho SR, Chang JW. Intrathecal Baclofen Pump Versus Globus Pallidus Interna Deep Brain Stimulation in Adult Patients with Severe Cerebral Palsy. World Neurosurg. 2019 Jun;126:e550-e556. [PubMed]
Dai AI, Wasay M, Awan S. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity. J Child Neurol. 2008 Dec;23(12):1464-6. [PubMed]
Sparks SE. Neonatal hypotonia. Clin Perinatol. 2015 Jun;42(2):363-71, ix. [PubMed]
Kaler J, Hussain A, Patel S, Majhi S. Neuromuscular Junction Disorders and Floppy Infant Syndrome: A Comprehensive Review. Cureus. 2020 Feb 08;12(2):e6922. [PMC free article] [PubMed]
Harris SR. Congenital hypotonia: clinical and developmental assessment. Dev Med Child Neurol. 2008 Dec;50(12):889-92. [PubMed]
Lisi EC, Cohn RD. Genetic evaluation of the pediatric patient with hypotonia: perspective from a hypotonia specialty clinic and review of the literature. Dev Med Child Neurol. 2011 Jul;53(7):586-99. [PubMed]
Peredo DE, Hannibal MC. The floppy infant: evaluation of hypotonia. Pediatr Rev. 2009 Sep;30(9):e66-76. [PubMed]
D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011 Nov 02;6:71. [PMC free article] [PubMed]
Cox N, Hinkle R. Infant botulism. Am Fam Physician. 2002 Apr 01;65(7):1388-92. [PubMed]
Bodensteiner JB. The evaluation of the hypotonic infant. Semin Pediatr Neurol. 2008 Mar;15(1):10-20. [PubMed]
Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurol Clin. 2015 Nov;33(4):831-46. [PMC free article] [PubMed]
Tuysuz B, Kartal N, Erener-Ercan T, Guclu-Geyik F, Vural M, Perk Y, Erçal D, Erginel-Unaltuna N. Prevalence of Prader-Willi syndrome among infants with hypotonia. J Pediatr. 2014 May;164(5):1064-7. [PubMed]
Refbacks
- There are currently no refbacks.